After years of anticipation, Botox’s biggest competitor has finally been approved by the FDA for cosmetic use in the U.S. Originally expected to be called Reloxin, abobotulinumtoxinA will available under the name Dysport.
Dysport is an acetylcholine release inhibitor that, like Botox, is derived from botulinum toxin. Injected into glabellar lines-those on the forehead and between the eyebrows-it acts as a neuromuscular blocking agent that softens wrinkles by relaxing muscle contractions. (Off-label uses on other areas have not yet been determined, but that shouldn’t take very long.)
Dysport is expected to be priced similarly to Botox, which some say doesn’t last as long or work as quickly as this new option due to a difference in protein levels. However, there is no unit translation, meaning you can’t refer to your current Botox dosage in order to determine how much Dysport to use.
When it becomes available within the next two months, patients will likely find that individual results vary; you may prefer Dysport while a friend stays loyal to Botox. Either way, it’s imperative that you visit a qualified dermatologist or plastic surgeon to administer either injectable.
Find a Doctor
Find a NewBeauty "Top Beauty Doctor" Near you